Efficacy Trial of Ambisome Given Alone and Ambisome Given in Combination With Miltefosine for the Treatment of VL HIV Positive Ethiopian Patients.
A Randomized Trial of Ambisome Monotherapy and Combination of Ambisome and Miltefosine for the Treatment of VL in HIV Positive Patients in Ethiopia Followed by Secondary VL Prophylactic Treatment With Pentamidine.
Sponsor: Addis Ababa University
Listed as NCT02011958, this PHASE3 trial focuses on Visceral Leishmaniasis and remains completed. Sponsored by Addis Ababa University, it has been updated 8 times since 2014, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
May 2019 — Jan 2021 [monthly]
Completed PHASE3
Status: Unknown Status → Completed
▶ Show 3 earlier versions
-
Jun 2018 — May 2019 [monthly]
Unknown Status PHASE3
-
Apr 2018 — Jun 2018 [monthly]
Unknown Status PHASE3
Status: Active Not Recruiting → Unknown Status
-
Jan 2017 — Apr 2018 [monthly]
Active Not Recruiting PHASE3
First recorded
Jul 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Addis Ababa University
- Drugs for Neglected Diseases
- Institute of Tropical Medicine, Belgium
- London School of Hygiene and Tropical Medicine
- Medecins Sans Frontieres, Netherlands
- Slotervaart Hospital
- University of Gondar
For direct contact, visit the study record on ClinicalTrials.gov .